JATT Acquisition Corp (JATT)
Price:
8.16 USD
( - -2.59 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)

(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Lucid Group, Inc.
VALUE SCORE:
0
2nd position
Jackson Acquisition Company II
VALUE SCORE:
8
The best
Colombier Acquisition Corp.
VALUE SCORE:
9
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.
NEWS

Reviewing Protalix BioTherapeutics (NYSE:PLX) & JATT Acquisition (NYSE:JATT)
defenseworld.net
2026-02-05 01:50:49Protalix BioTherapeutics (NYSE: PLX - Get Free Report) and JATT Acquisition (NYSE: JATT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations. Insider and Institutional Ownership 16.5% of Protalix
No data to display

Reviewing Protalix BioTherapeutics (NYSE:PLX) & JATT Acquisition (NYSE:JATT)
defenseworld.net
2026-02-05 01:50:49Protalix BioTherapeutics (NYSE: PLX - Get Free Report) and JATT Acquisition (NYSE: JATT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations. Insider and Institutional Ownership 16.5% of Protalix








